Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
B-cell targeted therapies, including anti-CD20 monoclonal antibodies (mAb) and Bruton's tyrosine kinase inhibitors (BTKi), further suppress antibody (Ab) response to vaccines in patients with chronic lymphocytic leukemia (CLL)...